Short Interest in Akari Therapeutics, Plc (NASDAQ:AKTX) Rises By 94.6%

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 144,200 shares, a growth of 94.6% from the December 15th total of 74,100 shares. Approximately 1.2% of the shares of the stock are sold short. Based on an average trading volume of 55,400 shares, the short-interest ratio is currently 2.6 days.

Analyst Ratings Changes

Separately, StockNews.com initiated coverage on Akari Therapeutics in a report on Monday. They set a “sell” rating on the stock.

Akari Therapeutics Stock Performance

Shares of Akari Therapeutics stock opened at $1.21 on Tuesday. The business has a fifty day simple moving average of $1.39 and a 200-day simple moving average of $2.58. Akari Therapeutics has a fifty-two week low of $0.90 and a fifty-two week high of $4.40.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.